Polyketal-conjugated tafluprost microparticles enable long-acting glaucoma therapy

Read full text
Authors: Haiping Zhong, Tuo Wei, Xueyan Zhou, Na Yu, Yoshiyuki Nakagawa, Claudia Santamaria, Akiva Gordon, Weiping Wang, Jingqing Mu, Changyou Zhan, Hanzhang Wang, Shuang‐Zhuang Guo
+6 more Shuang‐Zhuang Guo, Aoune Barhoumi, Xiaoyong Yuan, Daniel S. Kohane, Shutao Guo, Shutao Guo
Cited by: 1
References: 62

Abstract

Long-acting formulations are increasingly sought after for the management of chronic diseases. Drug-conjugated microparticles with degradation-controlled release present a promising modular extended-release platform that can be delivered through minimally invasive approaches. However, many conventional drug-conjugated microparticles have relatively short durations of release and substantial release of pharmacologically inactive drug-conjugated oligomers. Here, we present surface-erodible, drug-conjugated polyketal microparticles for extended release of unmodified pharmacologically active drug. Microparticles made of a polyketal conjugated to the anti-glaucoma agent tafluprost initially release unmodified tafluprost, then about two weeks later predominantly release the biologically active tafluprost acid due to the mildly base-catalyzed hydrolysis of tafluprost, with a cumulative total drug release of ~78% over 540 days in vitro. Notably, no detectable drug-conjugated oligomers are found in release medium. Tafluprost-polyketal conjugate microparticles that further encapsulate unconjugated tafluprost reduce intraocular pressure for approximately 3 months after subconjunctival injection in ocular normotensive female rats, exhibiting a low grade of tissue reaction, no retinal abnormalities or systemic side effects, and enhanced intraocular pressure-lowering efficacy compared with a long-acting bimatoprost-loaded biodegradable implant in an ocular hypertensive rat model. Our findings have broad implications in advancing extended drug delivery systems. Chronic diseases often need long-acting formulations to improve patient adherence. Here, the authors report a surface-erodible polyketal–tafluprost microparticle formulation that enables extended drug release, prolonged intraocular pressure reduction following a single subconjunctival injection, with good ocular biocompatibility, and enhanced efficacy verified in ocular hypertensive female rats.

Fields of Study & Subjects

Advanced Drug Delivery Systems Retinal Diseases and Treatments Retinal and Macular Surgery

Publication details

Journal / source
Nature Communications
Publisher
Springer Science and Business Media LLC
Volume
17
Issue
1
Publication date
29 April 2026
Language
EN